NUNZIUM

So far, cervical cancer screening has been the most successful personalized cancer prevention strategy. This type of screening aims to identify women with a pre-invasive lesion, which can be then surgically excised. Infection with human papillomavirus (HPV, which is sexually transmitted) could increase the risk of cancer of the cervix, vulva, and vagina. Today, many countries are adopting screening for human papillomavirus (HPV) as the primary investigation for cervical cancer. The test consists of the cytological analysis of a small biopsy of the cervix: high-risk HPV-positive women are identified and successive eventual treatment is determined. However, many patients are developing this type of cancer that are HPV-negative, implying that preventive diagnosis remains limited to a minority of cases. Scientists from the University of Innsbruck and University College London (UCL) developed a new screening test based on a DNA analysis that brings preventive diagnosis significantly beyond. The study, published in Genome Medicine, demonstrates a DNA methylation test of the cervical fluid capable of identifying women with a high risk of developing cervical, ovarian, and breast cancer. Such methodology opens the way to the more efficient and quick prediction of multiple cancer risks - and therefore a concrete possibility to a systematic early cancer diagnosis, the most important factor for increased chances of success in successive treatment.